Literature DB >> 21099351

TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.

Janhavi Gupta1, John Robbins, Tamas Jilling, Prem Seth.   

Abstract

We have delineated TGFβ signaling pathways in the production of osteolytic factors interleukin-8 and interleukin-11 in breast cancer cells with different bone metastases potential. Bone seeking MDA-MB-231(hm) cells expressed higher levels of IL-11, but lower levels of IL-8 compared to MDA-MB-231 cells. MCF-7 cells (mainly osteoblastic) did not express IL-8 or IL-11; MDA-MB-468 cells (weakly metastatic) expressed IL-8, but not IL-11. The up-regulation of IL-11 and IL-8 was associated with the rapid activation of SMAD2/3 and p38 MAPK through the TGFβ/TGFβR system. Analysis of TGFβ receptors indicated that MCF-7 cells do not express TGFβRII, and MDA-MB-468 cells do not express SMAD4. Inactivation of SMAD4 or p38PMAPK gene via RNAi resulted in the inhibition of IL-11 and IL-8 production in MDA-MB-231(hm) cells; and over-expression of SMAD4 gene resulted in IL-11 production in MDA-MB-468 cells. TGFβ-1 induced SMAD3 translocation to the nuclei in MDA-MB-231, MDA-MB-231(hm) as well as in SMAD4 deficient MDA-MB-468, indicating that an alternate non-canonical pathway could be responsible for TGFβ-1 induced cytokine production in MDA-MB-468 cells. Thus, four breast cancer cell lines used in this study show differential expression and up-regulation of the osteolytic factors in response to TGFβ-1 that involves both SMAD pathway, a non-canonical SMAD pathway, as well as p38 MAPK pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21099351      PMCID: PMC3047085          DOI: 10.4161/cbt.11.3.14096

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  22 in total

Review 1.  Inhibition of TGFbeta signaling in cancer therapy.

Authors:  Carlos L Arteaga
Journal:  Curr Opin Genet Dev       Date:  2005-12-27       Impact factor: 5.578

2.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Authors:  Manali S Bendre; Aaron G Margulies; Brandon Walser; Nisreen S Akel; Sudeepa Bhattacharrya; Robert A Skinner; Frances Swain; Vishnu Ramani; Khalid S Mohammad; Lisa L Wessner; Alfredo Martinez; Theresa A Guise; John M Chirgwin; Dana Gaddy; Larry J Suva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 3.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

Authors:  R E Coleman
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

4.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

Review 5.  Targeting TGFbeta signaling for cancer therapy.

Authors:  Sravisht Iyer; Zhen-Guo Wang; Mojtaba Akhtari; Wenli Zhao; Prem Seth
Journal:  Cancer Biol Ther       Date:  2005-03-28       Impact factor: 4.742

Review 6.  Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy.

Authors:  Swati Biswas; Tracy L Criswell; Shizhen Emily Wang; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

7.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

Review 8.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

9.  Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.

Authors:  D Katayose; J Gudas; H Nguyen; S Srivastava; K H Cowan; P Seth
Journal:  Clin Cancer Res       Date:  1995-08       Impact factor: 12.531

10.  A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.

Authors:  Z Hu; J S Robbins; A Pister; M B Zafar; Z-W Zhang; J Gupta; K J Lee; K Newman; K Neuman; C-O Yun; T Guise; P Seth
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more
  26 in total

1.  Breast cancer cells promote osteoblastic differentiation via Sema 3A signaling pathway in vitro.

Authors:  Wei-Wei Shen; Wu-Gui Chen; Fu-Zhou Liu; Xu Hu; Hong-Kai Wang; Ying Zhang; Tong-Wei Chu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  TGF-β1 and TNF-α synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation.

Authors:  Sheng-Jun Liao; Jing Luo; Dong Li; Yuan-Hong Zhou; Bin Yan; Jing-Jing Wei; Jian-Cheng Tu; Yi-Rong Li; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  J Cell Commun Signal       Date:  2019-02-09       Impact factor: 5.782

3.  Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.

Authors:  Yuefeng Yang; Weidong Xu; Thomas Neill; Zebin Hu; Chi-Hsiung Wang; Xianghui Xiao; Stuart R Stock; Theresa Guise; Chae-Ok Yun; Charles B Brendler; Renato V Iozzo; Prem Seth
Journal:  Hum Gene Ther       Date:  2015-11-10       Impact factor: 5.695

4.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Authors:  Barbara Onnis; Nicole Fer; Annamaria Rapisarda; Victor S Perez; Giovanni Melillo
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

5.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

6.  Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.

Authors:  Zebin Hu; Janhavi Gupta; Zhenwei Zhang; Helen Gerseny; Arthur Berg; Yun Ju Chen; Zhiling Zhang; Hongyan Du; Charles B Brendler; Xianghui Xiao; Kenneth J Pienta; Theresa Guise; Chung Lee; Paula H Stern; Stuart Stock; Prem Seth
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

7.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Authors:  Neil E Bhola; Justin M Balko; Teresa C Dugger; María Gabriela Kuba; Violeta Sánchez; Melinda Sanders; Jamie Stanford; Rebecca S Cook; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2013-02-08       Impact factor: 14.808

8.  Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway.

Authors:  Li Ren; Xia Wang; Zuoliang Dong; Jun Liu; Shiwu Zhang
Journal:  Med Oncol       Date:  2013-06-28       Impact factor: 3.064

Review 9.  Genetics of breast cancer bone metastasis: a sequential multistep pattern.

Authors:  Hassan Fazilaty; Parvin Mehdipour
Journal:  Clin Exp Metastasis       Date:  2014-02-04       Impact factor: 5.150

10.  LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.

Authors:  Weidong Xu; Yuefeng Yang; Zebin Hu; Maria Head; Kathy A Mangold; Megan Sullivan; Edward Wang; Poornima Saha; Kamalakar Gulukota; Donald L Helseth; Theresa Guise; Bellur S Prabhkar; Karen Kaul; Hans Schreiber; Prem Seth
Journal:  Hum Gene Ther       Date:  2020-06-12       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.